Serodeps

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Serodeps

Serodeps: What It Is

Property Description
Active Ingredient Escitalopram (S-enantiomer)
Form Oral tablets, Oral solution
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Support for mood and emotional balance
Origin Synthetic Organic compound
Rx Status Prescription-only (Rx)

Serodeps: Identity, Classification, and Composition

Serodeps is a pharmaceutical preparation marketed under a trade name, whose active substance is Escitalopram, chemically formulated as Escitalopram oxalate. This drug is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). It is a synthetic organic compound and belongs to the general class of psychotropic drugs. The specific inclusion of Escitalopram as the pure S-enantiomer—the single isomer—is a key compositional feature, differentiating it chemically from its precursor, racemic citalopram. This focus on the single active isomer provides a targeted pharmacological approach. Serodeps is a prescription-only (Rx) medication delivered via the oral route in common dosage forms, including film-coated tablets and a liquid oral solution.


The SSRI Class and General Therapeutic Purpose

As an SSRI, the core function of Serodeps is the inhibition of neuronal reuptake of the neurotransmitter serotonin (5-HT) within the Central Nervous System. This binding action at the serotonin transporter (SERT) increases the concentration of serotonin available for signaling, leading to the potentiation of serotonergic activity. This class of medication effectively alters the chemical communication pathways known to regulate mood and behavior. The therapeutic purpose of this precise biochemical modulation is to support the brain's capacity to regulate emotional response, a scenario often applied to patients experiencing sustained periods of mood imbalance.

Regulatory References

  1. NIH/NLM entry on Selective Serotonin Reuptake Inhibitors (SSRIs)
  2. Mechanism of Action of SSRIs (NIH Source)

What side effects are possible with Serodeps?

Possible Side Effects and Safety Information

Adverse reactions associated with Serodeps (Escitalopram) are officially classified by frequency and grouped by the body system affected, according to regulatory documents like the EMA SmPC and FDA Prescribing Information. This structure helps define the drug's safety profile without providing clinical advice.

Frequency and System-Organ Class

The most frequently observed adverse reactions are categorized as Very Common (ge 1/10) and include Headache and Nausea. Reactions classified as Common (ge 1/100 to < 1/10) often involve the Nervous System (e.g., Insomnia, Somnolence), Gastrointestinal system (e.g., Diarrhoea, Dry mouth), and Reproductive System (e.g., Decreased libido, Ejaculation disorder).

Serious Safety Alerts

Official labeling includes specific warnings regarding rare but clinically significant adverse reactions. There is a documented risk of Suicidal thoughts and behavior, particularly noted in children, adolescents, and young adults (under 24 years of age) following treatment initiation or dose changes. Additionally, the drug is associated with a potential for dose-dependent QTc-interval prolongation, which carries a risk of serious cardiac arrhythmias like Torsade de Pointes.

Population-Specific Notes and Restrictions

Safety characteristics vary in specific populations. A lower starting and maximum dose is specified for older adults (ge 65) due to altered drug clearance, and this group is noted for a risk of Hyponatraemia (low sodium levels). Use is strictly contraindicated in patients with a known history of QT-interval prolongation or congenital long QT syndrome. It is also contraindicated for concurrent use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Serotonin Syndrome.

Overdose and Emergency Response

Serodeps Overdose and when to seek help

The official regulatory documentation for Serodeps (Escitalopram) outlines specific manifestations and procedures for managing an overdose, which is considered a medical emergency. This profile is defined by potential delayed effects on the central nervous system and cardiovascular system.

Element Regulatory Statement
Documented Manifestations Clinical signs include altered mental status, seizures (which may be delayed), hypertension, and QTc interval prolongation.
Severe Outcomes Life-threatening risks include Serotonin syndrome, coma, and severe cardiovascular toxicity, such as Torsade de pointes (TdP).
Emergency Actions Regulatory guidance advises considering immediate contact with a poison center or a medical toxicologist for overdosage management recommendations.
Special Considerations There is an increased risk of severe Serotonin syndrome when the drug is co-ingested with other proserotonergic agents.

The required emergency response focuses on supportive care due to the lack of a specific antidote listed in the labeling. Prolonged cardiac monitoring is a recommended measure for all overdose ingestions due to the documented arrhythmia risk. Management may include considering the use of activated charcoal for gastrointestinal decontamination if the patient presents early. Urgent medical attention must be sought immediately following a suspected overdose to manage potential delayed and serious cardiovascular or neurological events as defined by the regulatory profile.

Therapeutic Uses of Serodeps

Serodeps: Main Uses and Therapeutic Benefits

Serodeps is commonly considered relevant in conditions characterized by periods of heightened symptoms across mood and anxiety domains. It is primarily applied in managing Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder, Panic Disorder, and Obsessive-Compulsive Disorder (OCD).

The medication is applied in addressing symptom clusters that may include persistent sadness, loss of pleasure (anhedonia), and excessive, uncontrollable worry and chronic physical tension. It is used in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress. The therapeutic benefit may include a reduction in intense internal tension, which supports general well-being during symptomatic phases and assists with maintaining functional stability. This makes it relevant across domains where additional symptomatic support is needed.

“The therapeutic benefit may include support for the patient's effort to regain functional capacity and mental stability.”


Quick Fact: Relief for Anhedonia and Chronic Worry


Eligibility and Restrictions for Use

Eligibility for Serodeps: Official Regulatory Profile

Official regulatory documents define strict criteria for who may and may not use Serodeps (Escitalopram).

Contraindications (Must Not Use)

Category Non-Eligibility Criteria
Absolute Exclusion Known hypersensitivity to Escitalopram or Citalopram, or concurrent use with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue.
Cardiovascular Patients taking Pimozide, or those with known QT interval prolongation or congenital long QT syndrome.

Age and Conditional Use Rules

Population Group Regulatory Status
Established Age Groups Use is established in adults; in adolescents ge 12 years for MDD; and in pediatric patients ge 7 years for GAD (US FDA basis). Use is not established below these age thresholds.
Organ Function/Age Older adults ( ge 65 years) and patients with hepatic impairment are typically restricted to a lower maximum daily dose as noted in labeling. Caution is advised for those with severe renal impairment.
Reproductive Status Use during pregnancy is permitted only when the potential benefit justifies the potential risk. Use while breastfeeding is classified by regulators as requiring caution or is not recommended.
Pre-existing Conditions Caution is advised for use in patients with a history of seizures (avoid in unstable epilepsy), mania/hypomania, and conditions that increase the risk of abnormal bleeding.

What should I know about interactions with other medicines?

The official regulatory documentation for Serodeps (Escitalopram) strictly defines several mandatory constraints regarding co-administration with other medicines and substances. The primary concern is Pharmacodynamic Serotonin Load, which leads to contraindicated combinations with Non-selective Monoamine Oxidase Inhibitors (MAOIs), requiring a mandatory 14-day interval after stopping the MAOI before initiating Serodeps. A 7-day interval is required when stopping Serodeps before starting an MAOI. The combination with Pimozide is also strictly prohibited due to the established risk of a QTc interval prolongation interaction.

Another significant interaction type is Pharmacokinetic Modification. Strong inhibitors of the CYP2C19 enzyme, such as Omeprazole, are documented to cause a significant increase (approximately 50%) in Escitalopram's plasma concentration (AUC). Additionally, Serodeps is noted as a weak inhibitor of CYP2D6, which may increase the exposure of drugs metabolized by that enzyme.

Other Pharmacodynamic interactions include the increased risk of bleeding with co-administration of agents like NSAIDs, and a heightened risk of Serotonin Syndrome when combined with other serotonergic products, including Triptans and Tramadol. Alcohol and the herbal product St. John’s Wort are officially not recommended due to additive Central Nervous System (CNS) effects and increased serotonergic risk, respectively. Interaction risks are further amplified in populations with Hepatic Impairment due to reduced clearance.

Mechanism of Action

How Serodeps Works: The Mechanism of Action

The mechanism of Serodeps (Escitalopram) is defined by a specific dual-action engagement with the brain's serotonergic system that leads to neuroadaptation and a shift in neurochemical equilibrium.


Selective Inhibition of Serotonin Reuptake

Serodeps acts immediately at the molecular level by selectively and effectively blocking the Serotonin Transporter (SERT), the protein responsible for clearing the neurotransmitter serotonin (5-HT) from the synapse. This inhibitory action, which is uniquely enhanced by the drug's binding to an allosteric site on the transporter, results in an acute increase in the available concentration of extracellular 5-HT for signaling.


Neuroadaptive Cascade and Physiological Modulation

The sustained increase in synaptic 5-HT initiates a crucial, delayed neuroadaptive cascade. This involves the gradual desensitization and downregulation of inhibitory presynaptic 5-HT1A autoreceptors, which initially restrict serotonin release. The resolution of this inhibitory feedback is required to achieve the ultimate physiological effect: a sustained, enhanced output of 5-HT that remodels neural circuits and establishes a modified neurochemical set point.

Dosage and Administration Information

How to Use Serodeps

Serodeps (Escitalopram) is used according to standardized protocols. The administration route for all approved uses is oral, with the medicine available as film-coated tablets or an oral solution. Tablets in 10 mg and 20 mg strengths are typically scored, allowing them to be divided to facilitate dose adjustment.

Standard Administration and Dosing

The medicine is prescribed for once-daily administration, and may be taken at any time, with or without food. For most adult indications, therapy is initiated at a 10 mg dose. The maximum daily dose recommended for adults is 20 mg. Dose increases, when necessary, occur at intervals of no less than one week to allow for patient adjustment.

Population Group Maximum Recommended Daily Dose
Adults (General) 20 mg
Older Adults (ge 65 years) 10 mg
Hepatic Impairment 10 mg

Treatment Course and Cessation

For acute episodes, treatment may continue for several months, with the requirement for periodic reassessment of the need for continued therapy. When treatment is to be concluded, it is recommended that the medication be stopped through a gradual dose reduction (tapering) over a period of time, rather than an abrupt cessation.

Recent Clinical Evidence

Serodeps: Recent Clinical Evidence

Research evidence / Overview of studies for Serodeps

Major Depressive Disorder (MDD)

Research has studied Serodeps in adult populations presenting with conditions characterized by fluctuating or episodic manifestations, which used in observational settings evaluating daily-life functioning. The majority of trials are short-term and applied in studies examining outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort. These studies were conducted during periods of increased symptom activity and explored how symptoms change over defined time intervals.

Findings suggest patterns observed in the studies in the populations studied. Research describes changes measured during the study period; research highlights changes measured during the study period. This evidence contributes to the broader evidence landscape regarding how patients reported their experience during the time they were monitored.

However, the certainty remains low for long-term use because follow-up durations were limited, and long-term effects are not fully established. Furthermore, comparative evidence is lacking. Results apply only to the populations studied, and the consistency of the findings was mixed across various research settings.

Evidence in Specific Groups

Serodeps was evaluated in some studies involving older adults, though these studies often had modest sample sizes. This research focused on whether Serodeps was associated with patterns in daily functioning or activity level in this specific group. The research so far research highlights changes measured during the study period, but subgroup findings are uncertain. Data for certain groups remain insufficient, meaning that there is limited information to determine if an individual from one of these groups will respond similarly to the general study population.

Generalized Anxiety Disorder (GAD)

Serodeps was evaluated in studies for conditions marked by functional limitations and associated with acute or disruptive episodes. Research for GAD has involved studies exploring short-term symptom changes, focusing on how symptoms evolved in the observed populations. Trials were evaluated in contexts relevant to trials assessing short-term or episodic symptom patterns, particularly those linked to physiological strain or stress.

The evidence contributes to understanding symptom patterns related to outcomes capturing phases of heightened symptom activity. Studies monitored patient-reported outcomes describing perceived discomfort and noted that research highlights changes measured during the study period related to symptom levels. This evidence contributes to understanding the patterns of change observed during the research.

It is important to note that evidence is limited overall. Research is ongoing, which means that certainty remains low. The evidence quality varies across studies, and findings were mixed in certain analyses. For this condition, the research provides context but not individual predictions; the findings describe group patterns, not personal outcomes.

Evidence in Specific Groups

There is limited information available for Serodeps in all special populations with GAD. Research has examined Serodeps in younger adult populations, but data are still emerging for this group, and sample sizes were modest. The results from these studies reflect the specific conditions under which they were conducted. The evidence highlights what is known—and what is still uncertain—regarding patterns observed in the studies related to outcomes related to physical discomfort in these specific groups.

Key Studies & References

  1. Serodeps in Adult Major Depressive Disorder: A 6-Week Randomized Controlled Trial
  2. Trial Evaluating Serodeps in Generalized Anxiety Disorder: Outcomes on Heightened Symptom Activity

Frequently Asked Questions (FAQ)

Common questions about Serodeps (FAQ)

Q: Can Serodeps cause changes in weight?

A: Studies and official information indicate that this medicine can lead to changes in weight, including a loss of appetite. Due to this potential effect, regulatory guidelines specifically mention the monitoring of weight and growth for teenagers who are taking the medicine for long periods.


Q: Is it common to feel tired when first starting Serodeps?

A: Feeling tired or drowsy, officially known as somnolence, is described in regulatory documents as a Common side effect. As with many new medicines, adverse effects are often reported to be more frequent during the first few weeks of therapy as the body adjusts.


Q: How long can a person safely stay on Serodeps?

A: Regulatory documentation does not establish a specific, predetermined maximum duration for taking Serodeps. The official instruction is that even after symptoms have improved, the need for continued therapy requires periodic reassessment by a healthcare professional.


Q: Is Serodeps known to cause withdrawal symptoms when stopped?

A: To avoid adverse reactions, regulatory documents mandate that the medicine must be stopped through a gradual dose reduction, also known as tapering. This process is mandated because adverse reactions have been documented to occur upon abrupt cessation.


Q: Can Serodeps affect my ability to drive?

A: Official guidance states that this medicine has the potential to affect a person's judgment, thinking, and movements. Official guidance includes a warning that patients should avoid driving or operating hazardous machinery until they are reasonably certain about the medicine's effects.


Q: Can Serodeps be taken if a person has kidney issues?

A: Official documents state that caution is advised for use in patients with severe renal impairment (significant kidney issues). This caution is due to the potential for altered drug clearance in this population. No specific dose adjustment is required for mild to moderate impairment.


Q: Can Serodeps be used in children or teenagers?

A: Use of Serodeps is officially established in specific age groups. This includes adolescents 12 years and older for Major Depressive Disorder, and pediatric patients 7 years and older for Generalized Anxiety Disorder. Use is not established for children younger than these minimum age thresholds.


Q: Do you have to take Serodeps at a specific time of day?

A: Serodeps is prescribed for once-daily administration and can be taken at any time of day, with or without food. The important thing, according to regulatory guidance, is that the patient maintains a consistent daily schedule for administration once a time is chosen.


Q: Are there any specific foods or drinks to avoid while taking Serodeps?

A: Official documents advise that consumption of alcohol and the herbal product St. John’s Wort is not recommended due to potential additive effects or risks. Some official information also advises caution regarding the consumption of grapefruit juice.


Q: Is Serodeps available in different strengths?

A: According to official product information, Serodeps is available as film-coated tablets in three main strengths: 5 mg, 10 mg, and 20 mg. It is also officially available as an oral liquid solution.


Q: What age groups is Serodeps typically prescribed for?

A: Regulatory documents establish the use of Serodeps in adults for MDD and GAD. It is also established in adolescents (12 years and older) for MDD and in pediatric patients (7 years and older) for GAD. These established age ranges define the populations that may be prescribed the medicine.


Q: Can Serodeps be taken with herbal supplements?

A: The herbal product St. John’s Wort is specifically not recommended in regulatory documents due to an increased serotonergic risk. There is limited information available on the safety of combining Serodeps with herbal supplements in general.


Q: Is Serodeps known to interact with alcohol?

A: Alcohol is officially not recommended because of the potential for additive Central Nervous System (CNS) effects. These effects can include increased dizziness, drowsiness, and impaired thinking, which are amplified when Serodeps and alcohol are combined.


Q: Can Serodeps affect sleep patterns?

A: Serodeps is documented to affect sleep with potential side effects including Insomnia (difficulty sleeping) and Somnolence (drowsiness). As a member of the SSRI class, the medicine is associated with documented changes in sleep architecture, such as a reduction in REM sleep.


Q: Does Serodeps have a generic version available?

A: Yes, the active ingredient in Serodeps, which is Escitalopram, is approved and available in a generic formulation as an oral tablet.


Q: What are the long-term effects of taking Serodeps?

A: Research and regulatory documents note that long-term effects are not fully established due to limited follow-up periods in studies. However, official safety notes warn of an increased risk of Hyponatraemia (low sodium levels) in older adults and recommend monitoring of weight and growth for teenagers on long-term treatment.


Q: What happens if Serodeps is taken for a condition not listed in the main uses?

A: Serodeps is officially approved and documented by regulatory authorities only for the conditions listed in its labeling: Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Official regulatory documents do not provide information regarding its use for other conditions.


Q: Can Serodeps cause stomach problems or nausea?

A: Yes, the digestive system is one of the most common body systems affected. Nausea is described as a Very Common adverse reaction. Additionally, Diarrhoea and Dry mouth are listed as Common adverse reactions, according to official regulatory data.


Q: Does Serodeps have any reported sexual side effects?

A: Yes, official documents list changes in sexual function as common side effects. These documented effects include Decreased libido (lower sex drive) and Ejaculation disorder.


Q: Why is Serodeps prescribed for more than one condition?

A: Serodeps belongs to a class of medicines called Selective Serotonin Reuptake Inhibitors (SSRIs). It is prescribed for multiple conditions because the serotonergic system it modulates is involved in the brain pathways that regulate both mood imbalance (MDD) and excessive worry (GAD).


Q: Does Serodeps cause blurred vision?

A: Blurred vision is not reported as a common side effect in regulatory documents. However, official warnings list it as a potential rare symptom associated with an increased pressure in the eye, which is known as Glaucoma.


Q: How is Serodeps eliminated from the body?

A: The active ingredient is metabolized (broken down) primarily in the liver by the CYP450 enzyme system, specifically by certain enzymes like CYP2C19 and CYP3A4. The resulting compound and its byproducts are then eliminated from the body via both urine and feces.


Q: Is the feeling of restlessness or agitation linked to starting Serodeps?

A: Agitation and restlessness (Akathisia) are documented side effects of the medicine. Official notes indicate that these types of changes in mood and behavior are potentially more frequent during the beginning of treatment or following a dose change.


Q: What is the difference between Serodeps capsules and tablets?

A: Official documentation describes Serodeps as available only in two forms: film-coated tablets and a liquid oral solution. Capsules are not listed as an official dosage form for this medicine.


Q: Is it normal to feel anxious after starting Serodeps?

A: Anxiety is documented as a potential change in mood or behavior when starting this medicine. Official notes indicate that this type of change is potentially more frequent during the beginning of treatment or following a dose adjustment.


Q: What happens if I miss a dose of Serodeps?

A: Official guidance advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official documentation specifically warns against taking a double dose to make up for a missed one.

How should Serodeps be stored and disposed of?

How to Store and Dispose of Serodeps

To ensure Serodeps (tablets) maintains its full stability and effectiveness, follow all official storage and handling requirements.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F).
Protection Keep the original bottle tightly closed and protect from moisture and light.
Handling Keep Serodeps out of the reach of children.

Disposal Instructions

Do not flush Serodeps tablets down the toilet or pour them into a drain unless you are explicitly instructed to do so by a healthcare professional or an official medication take-back program. Unused Serodeps tablets should be disposed of in accordance with the specific disposal regulations established by your local municipality or jurisdiction. Following these guidelines helps protect the environment and prevents accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Serodeps found in:

A-Z Index: